Kevin Cissy Nabukeera

Kevin Cissy Nabukeera

Auto-generated profile, based on publicly available information

Kevin Cissy Nabukeera

African Center of Excellence in Bioinformatics and Data-Intensive Science; Infectious Disease Institute; Makerere University

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
KNKevin Cissy Nabukeera
Kevin Cissy Nabukeera
GLGradi Luakanda-Ndelemo
Gradi Luakanda-Ndelemo
SSSyrus Semawule
Syrus Semawule
AAAlisen Ayitewala
Alisen Ayitewala
PAPascal Adroba-Tandele
Pascal Adroba-Tandele
ISIsaac Ssewanyana
Isaac Ssewanyana
The 2026 Bundibugyo virus disease (BVD) outbreak in the DRC and Uganda raises urgent questions about the efficacy of existing Ebola virus (EBOV) monoclonal antibodies (mAbs) against Bundibugyo virus (BDBV). Here, we perform genomic and structural analyses of 44 BDBV sequences, including 12 from the 2026 outbreak, to assess mAb binding to the viral glycoprotein (GP). While the MBP134 cocktail epitopes remain conserved, mAb114 (Ebanga) binding is compromised by E112D and P116A mutations, causing off-target binding and reduced affinity. Structural modeling of Inmazeb shows that while Odesivimab maintains epitope binding, Atoltivimab and Maftivimab fail to bind their designated sites individually, though the complete trimeric cocktail demonstrates BDBV synergistic binding. These computational models predict mAb114 efficacy against BDBV may be compromised due to epitope mutations affecting binding affinity, whereas MBP134 retains conserved targeting and holds promise as a broadly protective therapeutic. The complex binding behavior of Inmazeb components points to the importance of antibody combinatorial effects for treatment efficacy. These observations warrant urgent experimental validation through neutralization assays.

15 July 2026 in Research Square
Verified
Preprint
Open access
DJDaudi Jjingo
Daudi Jjingo
KNKevin Cissy Nabukeera
Kevin Cissy Nabukeera
GLGradi Luakanda-Ndelemo
Gradi Luakanda-Ndelemo
SSSyrus Semawule
Syrus Semawule
PTPascal Adroba Tandele
Pascal Adroba Tandele
ISIsaac Ssewanyana
Isaac Ssewanyana
The 2026 Bundibugyo virus disease (BVD) outbreak in the DRC and Uganda raises urgent questions about the efficacy of existing Ebola virus (EBOV) monoclonal antibodies (mAbs) against Bundibugyo virus (BDBV). Here, we perform genomic and structural analyses of 44 BDBV sequences, including 12 from the 2026 outbreak, to assess mAb binding to the viral glycoprotein (GP). While the MBP134 cocktail epitopes remain conserved, mAb114 (Ebanga) binding is compromised by E112D and P116A mutations, causing off-target binding and reduced affinity. Structural modeling of Inmazeb shows that while Odesivimab maintains epitope binding, Atoltivimab and Maftivimab fail to bind their designated sites individually, though the complete trimeric cocktail demonstrates BDBV synergistic binding. These findings suggest that mAb114 could have reduced efficacy against BDBV due to epitope mutations affecting binding affinity, whereas MBP134 retains conserved targeting and holds promise as a broadly protective therapeutic. The complex binding behavior of Inmazeb components points to the importance of antibody combinatorial effects for treatment efficacy and warrants urgent experimental validation through neutralization assays.

4 November 2026 in Research Square
Verified
Preprint
Open access
PDF file
AWAndrew Walakira
Andrew Walakira
RGRonald Galiwango
Ronald Galiwango
BNBrenda Namugamba
Brenda Namugamba
SKShahiid Kiyaga
Shahiid Kiyaga
KNKevin Cissy Nabukeera
Kevin Cissy Nabukeera
DJDaudi Jjingo
Daudi Jjingo
Artemisinin-based combination therapies (ACTs) have substantially reduced the global burden of malaria, but the emergence and spread of artemisinin partial resistance (ART-R) threatens these gains. Although mutations in Plasmodium falciparum kelch13 (pfk13) are established mediators of ART-R, they do not fully explain variation in parasite responses, highlighting the need for complementary markers. We integrated six independent intra-erythrocytic developmental cycle (IDC) transcriptomic datasets by harmonic regression and random-effects meta-analysis, followed by network analyses, protein structural modelling, population genomics and ex vivo dihydroartemisinin susceptibility data, to identify candidate P. falciparum polymorphisms associated with artemisinin response. The meta-analysis identified 2,842 of 5,292 genes as significantly rhythmic across the 48-hour IDC, including those encoding PfK13 and PfMDR1. Integration with whole-genome sequences of Ugandan field isolates prioritized 13 nonsynonymous variants across 10 genes, encoding PfAP2-G, PfPX1, PfACS7, PfACS1a, PfRESA3, PfDRPC and PfA8IJP together with three proteins of unknown function, all transcriptionally co-timed with pfk13. Polymorphisms in pfpx1 have independently been implicated in artemisinin susceptibility, consistent with our prioritization. These candidates are potential complementary mediators of artemisinin response. Beyond them, the pipeline itself is transferable to other resistance phenotypes and periodic transcriptional programmes.